대한부인종양학회

최신 논문

총 게시글 : 44

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study 2023-06-29 VIEW : 14
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial 2023-03-29 VIEW : 35
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial 2023-03-29 VIEW : 34
NItrogen-based bisphosphonate use ad ovarian cancer risk in women aged 50 years and older 2022-10-13 VIEW : 87
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial 2022-06-28 VIEW : 79
Association of Germiline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data 2022-03-30 VIEW : 61
SUCCOR cone study: conization before radical hysterectomy 2022-02-14 VIEW : 79
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer 2021-12-20 VIEW : 47
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial 2021-12-20 VIEW : 34
Long-Term Risk of Ovarian Cancer and Borderline Tumors After Assisted Reproductive Technology 2021-08-19 VIEW : 63
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study 2021-08-02 VIEW : 38
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial 2021-04-27 VIEW : 65
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial 2021-04-27 VIEW : 50
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39) 2021-04-27 VIEW : 59

1
2
3